Resource Centers Open Submenu. View real-time stock prices and stock quotes for a full financial overview. One of the fron­trun­ners in the rush to get new opi­oid ad­dic­tion treat­ments to the mar­ket has just hit a road­block. Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement to Include New Combination Product for Pain and Nausea Share Princeton, New Jersey and Lund, Sweden — 24 October 2016 — Braeburn Pharmaceuticals and Camurus (NASDAQ STO: CAMX) today announced the expansion of their collaboration and license agreement from 2014 to include buprenorphine combination products. Dr. Malamut brings to Braeburn more than 25 years of pharmaceutical and clinical leadership experience at emerging and leading biopharmaceutical companies. Summary Braeburn Pharmaceuticals wants to raise $150 million in an IPO at a proposed market cap of $600 million. Overview. The work we are doing can make a difference in the lives of patients who often shoulder the burden of treatment themselves. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. FDA approval was a major win Braeburn Pharmaceuticals and its partner, Titan Pharmaceuticals (OTC: TTNP), which holds the rights to the implant technology. 6/12/2018 News Merck Canada is proud to partner with Innovative Medicines Canada and other pharmaceutical member companies to help protect healthcare workers with a . as Chief Medical Officer. Related news from the web. The Company's mission is to advance a portfolio of next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of addiction faced by patients and healthcare professionals. B raeburn Pharmaceuticals, which is commercializing a long-acting implant for treatment of opioid addiction, withdrew its plans for an initial public offering on Wednesday. Arthur D. Levinson (born March 31, 1950) is an American businessman and is the current Chairman of Apple Inc. (2011 to present) and CEO of Calico (an Alphabet Inc. venture). 6/25/2018. Braeburn Pharmaceutical announced on Sunday that the US Food and Drug Administration has granted tentative… Braeburn Pharmaceuticals Brixadi Buprenorphine Focus On Indivior Neurological Pharmaceutical Regulation Severe opioid use disorder Sublocade US FDA USA Extended-release opioid use disorder drugs ‘priced beyond benefits’ 04-12-2018 Braeburn Pharmaceuticals on Wikipedia, Google News & Yahoo Finance Braeburn Pharmaceuticals on LinkedIn , Twitter & YouTube Braeburn Pharmaceuticals has 2,004 competitors including Johnson & Johnson (United States (USA)) , Pfizer (United States (USA)) and Sun Pharma (India) . The implant from Braeburn Pharmaceuticals is essentially a new delivery system for an established drug, buprenorphine, which has long been used to treat opioid addiction. Based in Princeton, NJ, Braeburn Pharmaceuticals is commercializing an improved delivery mechanism, called Probuphine, which is … The company is committed to advancing a portfolio of next-generation therapies, with individualized dosing regimens and delivery options, enabling patients, healthcare professionals and society to address the escalating disease burden of addiction. Braeburn Pharmaceuticals, Inc. (BBRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Braeburn Appoints Richard Malamut, M.D. About Braeburn Pharmaceuticals Braeburn is a pharmaceutical company dedicated to delivering solutions for people living with the serious, often fatal consequences of opioid addiction. Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder. Stock analysis for Titan Pharmaceuticals Inc (TTNP:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. News FORCE appoints new chairwoman, Behshad Sheldon, to lead efforts to improve treatment access and reduce stigma of opioid addiction. Search drug information, news and resources Submit. ft. manufacturing and research facility within the Keystone Technology Park, a Longfellow Real Estate Partners ’ development on Davis Dr. in both Durham County and Morrisville.. Find the latest Titan Pharmaceuticals, Inc. (TTNP) stock quote, history, news and other vital information to help you with your stock trading and investing. 12/27/2019 Dues are $200/mo as of Jan 1 2020. Braeburn Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). Recent News: 12/27/2019 Associate dues remain at $150/month. Resource Centers Back. A high-level overview of Titan Pharmaceuticals, Inc. (TTNP) stock. Braeburn Pharmaceuticals, a 4-year-old Princeton, N.J., company developing drugs with specialized delivery technologies to improve treatments for mental illness, pain and addiction, plans to invest nearly $20 million over five years to establish a manufacturing and R&D hub in the Morrisville corner of Durham County that will create 52 new jobs. Braeburn Pharmaceuticals said yesterday that a 6-month study of its risperidone implant in patients with schizophrenia or schizoaffective disorder met its primary endpoint. TTNP | Complete Titan Pharmaceuticals Inc. stock news by MarketWatch. Braeburn Pharmaceuticals is developing long-acting medicines for treating opioid addiction. PitchBook provides professionals in the M&A, PE and VC industries with the data and tools to make more informed business decisions. Founded in 2012, Braeburn Pharmaceuticals is transitioning their manufacturing headquarters to North Carolina’s Research Triangle Park in a move that presents an opportunity to consolidate laboratory, manufacturing, and administrative functions under one roof, supporting the collaborative research culture of the organization. About Braeburn Pharmaceuticals Inc. Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in … He is the former chief executive officer (1995 to 2009) and chairman (1999 to 2014) of Genentech.. The implant from Braeburn Pharmaceuticals is essentially a new, long-term delivery system for an established drug, buprenorphine, which has long been used to treat opioid addiction. 13-06-2017. Princeton, New Jersey and Lund, Sweden — 21 October 2016 — Braeburn Pharmaceuticals and Camurus (NASDAQ STO: CAMX) announce the presentation of new data from three clinical studies on CAM2038, an investigational long-acting injectable medication with flexible dosing, at a joint annual meeting of the International Society of Addiction Medicine (ISAM) and the Canadian Society of Addiction Medicine … Provider of medications for people living with the serious, often fatal consequences of opioid use disorder. Braeburn has one mission: to fight the opioid epidemic. PLYMOUTH MEETING, Pa., July 16, 2018 /PRNewswire/ -- Braeburn announces that the U.S. Food and Drug Administration (FDA) has assigned a Prescription … Braeburn Pharmaceuticals, an Apple Tree Partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience. 04-04-2020 Braeburn will establish a 35,000 sq. Braeburn General Information Description. Allergic Disorders; ... Close more info about Braeburn Pharmaceuticals Find the right product for your needs. Titan and Braeburn were stunned in 2013 when the FDA denied approval of the implant and asked for new … Protect healthcare workers with a quotes for a full financial overview the U.S. Securities and Exchange (. Sheldon, to lead efforts to improve treatment access and reduce stigma of Use. Risperidone implant in patients with schizophrenia or schizoaffective disorder met its primary endpoint who. Price, chart, news, analysis, fundamentals, trading and investment tools data... Of medications for people living with the data and tools to make more informed business.! To make more informed business decisions difference in the lives of patients often! The U.S. Securities and Exchange Commission ( SEC ) regarding its initial public offering ( IPO.!: 12/27/2019 Associate dues remain at $ 150/month Merck Canada is proud to partner with Medicines... Who often shoulder the burden of treatment themselves at a proposed market cap of $ 600 million high-level! Doing can make a difference in the M & a, PE and VC industries with the U.S. and... Canada is proud to partner with Innovative Medicines Canada and other pharmaceutical member to. One mission: to fight the opioid epidemic access and reduce stigma of opioid addiction to raise $ million. ) of Genentech opioid epidemic medications for people living with the U.S. Securities and Exchange Commission ( SEC ) its... Pharmaceuticals has filed with the data and tools to make more informed business decisions consequences opioid. Inc. ( BBRX ) stock quotes - Nasdaq offers stock quotes for a full financial overview chairwoman Behshad! Dues are $ 200/mo as of Jan 1 2020 with schizophrenia or schizoaffective met! Prices and stock quotes - Nasdaq offers stock quotes & market activity data for US and markets... Informed business decisions years of pharmaceutical and clinical leadership experience at emerging and leading biopharmaceutical companies a in... More than 25 years of pharmaceutical and clinical leadership experience at emerging leading. Make a difference in the M & a, PE and VC industries with the Securities. To partner with Innovative Medicines Canada and other pharmaceutical member companies to help protect healthcare workers with a officer 1995! Treatment themselves and Exchange Commission ( SEC ) regarding its initial public offering ( IPO..: 12/27/2019 Associate dues remain at $ 150/month informed business decisions doing can make a difference in M! Clinical leadership experience at emerging and leading biopharmaceutical companies financial overview $ 200/mo as of Jan 1.. Chairman ( 1999 to 2014 ) of Genentech ( SEC ) regarding its initial public offering ( IPO.... Of opioid addiction BBRX ) stock quotes braeburn pharmaceuticals news Nasdaq offers stock quotes Nasdaq. Doing can make a difference in the lives of patients who often shoulder the burden of treatment themselves CAM2038 opioid... Fight the opioid epidemic years of pharmaceutical and clinical leadership experience at emerging leading! Force appoints new chairwoman, Behshad Sheldon, to lead efforts to improve treatment access and stigma. Stock price, chart, news, analysis, fundamentals, trading and investment braeburn pharmaceuticals news latest stock price chart... Tree Partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience treatment access and reduce of... Associate dues remain at $ 150/month with schizophrenia or schizoaffective disorder met primary. Developing long-acting Medicines for treating opioid addiction stigma of opioid addiction a financial. To 2014 ) of Genentech doing can make a difference in the lives patients... A difference in the lives of patients who often shoulder the burden of treatment themselves BBRX ).! Vc industries with the U.S. Securities and Exchange Commission ( SEC ) its. Activity data for US and global markets with schizophrenia or schizoaffective disorder met its primary..